Drugs / AWT020
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06839105 | Feb 2025 → Apr 2028 expected | colorectal cancer, non-small cell lung carcinoma, renal cell adenocarcinoma | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06092580 | Sep 2023 → Jun 2026 overdue | cancer of unknown primary site | Anwita Biosciences | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AWT020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06092580 ↗ |
| Route | Intravenous | “receive AWT020 via intravenous infusion” NCT06092580 ↗ |